TENK Overview

Market Resilience: Despite a recent market downturn influenced by recession fears and tech stock volatility, the S&P 500 showed resilience with some stocks, like Latham Group and Lumen Technologies, experiencing significant gains, indicating potential investment opportunities.

TenX Keane Acquisition Surge: TenX Keane Acquisition saw a remarkable 275% increase in stock value following its merger approval with Citius Pharmaceuticals, although trading has been halted pending further information from Nasdaq, highlighting the speculative nature of SPAC investments.

FDA Approval and Merger Announcement: Citius Pharmaceuticals has received FDA approval for LYMPHIR™, a treatment for cutaneous T-cell lymphoma, and completed a merger with TenX Keane Acquisition to form Citius Oncology, which will begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024.

Future Growth Potential: The merger is expected to enhance financial flexibility for Citius Oncology, allowing it to focus on launching LYMPHIR and exploring additional oncology assets, while Citius Pharma aims to develop other products in its portfolio.

Palantir Technologies Performance: Palantir Technologies Inc. shares rose 9.6% in pre-market trading after reporting second-quarter revenue of $678.13 million, surpassing estimates, along with adjusted earnings of 9 cents per share.

Market Movements: Several stocks experienced significant pre-market trading changes, with Lytus Technologies and Lumen Technologies gaining 79.1% and 44.8%, respectively, while SunPower Corporation saw a decline of 24.6% following its Chapter 11 filing.

U.S. Stock Market Performance: U.S. stocks fell significantly, with the S&P 500 dropping over 100 points and major indices like the Dow and NASDAQ declining by 2.3% and 3.19%, respectively. Notable movements included Kellanova shares rising 15% due to acquisition speculation, while Actinium Pharmaceuticals saw a 64% drop after FDA trial news.

Global Market Trends: European and Asian markets also experienced declines, with the eurozone's STOXX 600 falling 2.17% and Japan's Nikkei 225 dipping 12.4%. Additionally, commodity prices for oil, gold, silver, and copper all decreased on Monday.

Merger Approval: TenX Keane shareholders approved the merger with Citius Oncology, which will result in a new company named Citius Oncology, Inc. trading on Nasdaq, expected to enhance commercialization efforts for its oncology product LYMPHIR.

Financial and Strategic Implications: The merger is anticipated to provide better access to public equity markets, support the development of LYMPHIR for treating cutaneous T-cell lymphoma, and explore additional oncology opportunities, with Citius Pharma retaining approximately 90% ownership post-merger.